CoChat
Sign Up
Cited by 123Gut microbiota and healthLiver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?

Open access
Betrapally, Naga S., Gillevet, Patrick M., Bajaj, Jasmohan S.·2016·Gastroenterology
DOI 10.1053/j.gastro.2016.02.073PMC PMC5026236
Open this paper in CoChat — free account

Abstract

The prevalence of fatty liver diseases is increasing rapidly worldwide; after treatment of hepatitis C virus infection becomes more widespread, fatty liver diseases are likely to become the most prevalent liver disorders. Although fatty liver diseases are associated with alcohol, obesity, and the metabolic syndrome, their mechanisms of pathogenesis are not clear. The development and progression of fatty liver, alcoholic, and nonalcoholic liver disease (NAFLD) all appear to be influenced by the composition of the microbiota. The intestinal microbiota have been shown to affect precirrhotic and cirrhotic stages of liver diseases, which could lead to new strategies for their diagnosis, treatment, and study. We review differences and similarities in the cirrhotic and precirrhotic stages of NAFLD and alcoholic liver disease. Differences have been observed in these stages of alcohol-associated disease in patients who continue to drink compared with those who stop, with respect to the composition and function of the intestinal microbiota and intestinal integrity. NAFLD and the intestinal microbiota also differ between patients with and without diabetes. We also discuss the potential of microbial therapy for patients with NAFLD and ALD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2016.02.073

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • FGF15/19 modulates host metabolism and bile acid synthesis in the liver.

    “FGF15/19 has been found to modulate host metabolism and bile acid synthesis in the liver (Betrapally et al., 2016).”

    From <i>Akkermansia muciniphila</i> alleviates <scp>high‐fat‐diet</scp> ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids (2023) · cites this paper as Betrapally et al., 2016

    In “Role of microbiota in digestion and effect of bile acids” (page unavailable), Fgf15 appears only among genes whose expression correlated with FXR-mediated protection of the mouse intestine. The copy discusses liver metabolism and bile acids elsewhere, but the passages found for FGF15/19 and hepatic bile-acid synthesis do not say that FGF15/19 modulates either process. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 99 · Cited by 123

Research works printed but not linked: 77

  1. [2]Turnbaugh PJ Gordon JI The core gut microbiome, energy balance and obesity J Physiol 587 4153 4158 2009 19491241 PMC2754355
  2. [3]Qin J A human gut microbial gene catalogue established by metagenomic sequencing Nature 464 59 65 2010 20203603 PMC3779803
  3. [4]Neish AS Microbes in gastrointestinal health and disease Gastroenterology 136 65 80 2009 19026645 PMC2892787
  4. [5]Henao-Mejia J Elinav E Thaiss CA Flavell RA The intestinal microbiota in chronic liver disease Adv Immunol 117 73 97 2013 23611286
  5. [6]Prawitt J Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity Diabetes 60 1861 1871 2011 21593203 PMC3121443
  6. [7]Salyers AA Gherardini F O’Brien M Utilization of xylan by two species of human colonic Bacteroides Appl Environ Microbiol 41 1065 1068 1981 7235704 PMC243861
  7. [8]Prabha V Ohri M Review: Bacterial transformations of bile acids World J Microbiol Biotechnol 22 191 196 2005
  8. [9]Yadav H Lee JH Lloyd J Walter P Rane SG Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion J Biol Chem 288 25088 25097 2013 23836895 PMC3757173
  9. [12]Islam KBMS Bile acid is a host factor that regulates the composition of the cecal microbiota in rats Gastroenterology 141 1773 1781 2011 21839040
  10. [14]Dubé PE Brubaker PL Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators Am J Physiol Endocrinol Metab 293 E460 465 2007 17652153
  11. [15]Shi X Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons Cell Metab 18 86 98 2013 23823479 PMC3752162
  12. [16]Ley RE Obesity alters gut microbial ecology Proc Natl Acad Sci U S A 102 11070 11075 2005 16033867 PMC1176910
  13. [17]Ley RE Turnbaugh PJ Klein S Gordon JI Microbial ecology: human gut microbes associated with obesity Nature 444 1022 1023 2006 17183309
  14. [18]Zhang X Human gut microbiota changes reveal the progression of glucose intolerance PloS One 8 e71108 2013 24013136 PMC3754967
  15. [19]Qin J A metagenome-wide association study of gut microbiota in type 2 diabetes Nature 490 55 60 2012 23023125
  16. [21]Flint HJ Obesity and the gut microbiota J Clin Gastroenterol 45 S128 S132 2011 21992951
  17. [22]Finelli C Tarantino G Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients? J Gastrointest Liver Dis JGLD 21 293 302 2012 23012671
  18. [23]Wolf G Gut microbiota: a factor in energy regulation Nutr Rev 64 47 50 2006 16491670
  19. [24]DiBaise JK Gut microbiota and its possible relationship with obesity Mayo Clin Proc 83 460 469 2008 18380992
  20. [25]Kallus SJ Brandt LJ The intestinal microbiota and obesity J Clin Gastroenterol 46 16 24 2012 22064556
  21. [26]Kalliomäki M Collado MC Salminen S Isolauri E Early differences in fecal microbiota composition in children may predict overweight Am J Clin Nutr 87 534 538 2008 18326589
  22. [28]Vanni E From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 42 320 330 2010 20207596
  23. [29]Bellentani S Scaglioni F Marino M Bedogni G Epidemiology of Non-Alcoholic Fatty Liver Disease Dig Dis 28 155 161 2010 20460905
  24. [30]Gregor MF Hotamisligil GS Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease J Lipid Res 48 1905 1914 2007 17699733
  25. [32]Maher JJ New insights from rodent models of fatty liver disease Antioxid Redox Signal 15 535 550 2011 21126212 PMC3118700
  26. [33]Vinolo MAR Rodrigues HG Nachbar RT Curi R Regulation of inflammation by short chain fatty acids Nutrients 3 858 876 2011 22254083 PMC3257741
  27. [34]Tilg H Obesity, metabolic syndrome, and microbiota: multiple interactions J Clin Gastroenterol 44 Suppl 1 S16 18 2010 20535027
  28. [35]Bajaj JS Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus Sci Rep 5 18559 2015 26692421 PMC4686976
  29. [37]Farhadi A Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis Liver Int Off J Int Assoc Study Liver 28 1026 1033 2008 PMC4303249 18397235
  30. [39]Bala S Marcos M Gattu A Catalano D Szabo G Acute Binge Drinking Increases Serum Endotoxin and Bacterial DNA Levels in Healthy Individuals PLoS ONE 9 e96864 2014 24828436 PMC4020790
  31. [40]Rivera CA Bradford BU Seabra V Thurman RG Role of endotoxin in the hypermetabolic state after acute ethanol exposure Am J Physiol 275 G1252 1258 1998 9843760
  32. [41]Chen P Microbiota Protects Mice Against Acute Alcohol-Induced Liver Injury Alcohol Clin Exp Res 2015 10.1111/acer.12900 PMC4712135 26556636 · DOI
  33. [42]Bode JC Bode C Heidelbach R Dürr HK Martini GA Jejunal microflora in patients with chronic alcohol abuse Hepatogastroenterology 31 30 34 1984 6698486
  34. [43]Bjarnason I Peters TJ Wise RJ The leaky gut of alcoholism: possible route of entry for toxic compounds Lancet Lond Engl 1 179 182 1984 6141332
  35. [44]Keshavarzian A Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage Am J Gastroenterol 94 200 207 1999 9934756
  36. [45]Parlesak A Schäfer C Schütz T Bode JC Bode C Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease J Hepatol 32 742 747 2000 10845660
  37. [46]Fukui H Brauner B Bode JC Bode C Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay J Hepatol 12 162 169 1991 2050995
  38. [47]Roh YS Seki E Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis J Gastroenterol Hepatol 28 Suppl 1 38 42 2013 23855294 PMC3721430
  39. [48]Mutlu EA Colonic microbiome is altered in alcoholism Am J Physiol Gastrointest Liver Physiol 302 G966 978 2012 22241860 PMC3362077
  40. [49]Leclercq S Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity Proc Natl Acad Sci U S A 111 E4485 E4493 2014 25288760 PMC4210345
  41. [50]Napolitano LM Chronic ethanol intake and burn injury: evidence for synergistic alteration in gut and immune integrity J Trauma 38 198 207 1995 7869435
  42. [51]Yan AW Enteric dysbiosis associated with a mouse model of alcoholic liver disease Hepatol Baltim Md 53 96 105 2011 PMC3059122 21254165
  43. [52]Mutlu E Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats Alcohol Clin Exp Res 33 1836 1846 2009 19645728 PMC3684271
  44. [53]Bull-Otterson L Metagenomic Analyses of Alcohol Induced Pathogenic Alterations in the Intestinal Microbiome and the Effect of Lactobacillus rhamnosus GG Treatment PLoS ONE 8 e53028 2013 23326376 PMC3541399
  45. [54]Xie G Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption FASEB J Off Publ Fed Am Soc Exp Biol 27 3583 3593 2013 PMC3752538 23709616
  46. [55]Kakiyama G Colonic inflammation and secondary bile acids in alcoholic cirrhosis Am J Physiol Gastrointest Liver Physiol 306 G929 937 2014 24699327 PMC4152166
  47. [56]Jaruvongvanich V Upala S Sanguankeo A Association between systemic inflammatory response syndrome and mortality in alcoholic hepatitis: A meta-analysis Hepatol Baltim Md 2015 10.1002/hep.28366 26645856 · DOI
  48. [57]Llopis M Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease Gut 2015 10.1136/gutjnl-2015-310585 26642859 · DOI
  49. [58]Bajaj JS Altered profile of human gut microbiome is associated with cirrhosis and its complications J Hepatol 60 940 947 2014 24374295 PMC3995845
  50. [59]Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet Lond Engl 368 1696 1705 2006 17098089
  51. [61]Wilkins JJ Dubar M Sébastien B Laveille C A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes J Clin Pharmacol 54 267 278 2014 24122776
  52. [62]Sebokova E Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat Diabetes Obes Metab 12 674 682 2010 20590744
  53. [63]Aguilar RB Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success Clin Ther 33 408 424 2011 21635988
  54. [65]Alisi A Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis Aliment Pharmacol Ther 39 1276 1285 2014 24738701 PMC4046270
  55. [66]Li Z Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease Hepatol Baltim Md 37 343 350 2003 12540784
  56. [67]Swann JR Systemic gut microbial modulation of bile acid metabolism in host tissue compartments Proc Natl Acad Sci U S A 108 Suppl 1 4523 4530 2011 20837534 PMC3063584
  57. [68]Wong VWS Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study Ann Hepatol 12 256 262 2013 23396737
  58. [69]Endo H Niioka M Kobayashi N Tanaka M Watanabe T Butyrate-Producing Probiotics Reduce Nonalcoholic Fatty Liver Disease Progression in Rats: New Insight into the Probiotics for the Gut-Liver Axis PLoS ONE 8 e63388 2013 23696823 PMC3656030
  59. [70]Jin CJ Sellmann C Engstler AJ Ziegenhardt D Bergheim I Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH) Br J Nutr 114 1745 1755 2015 26450277
  60. [72]Neuschwander-Tetri BA Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet Lond Engl 385 956 965 2015 PMC4447192 25468160
  61. [73]Adachi Y Moore LE Bradford BU Gao W Thurman RG Antibiotics prevent liver injury in rats following long-term exposure to ethanol Gastroenterology 108 218 224 1995 7806045
  62. [74]Zhou Z A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF-alpha production Am J Pathol 163 1137 1146 2003 12937155 PMC1868249
  63. [75]Kirpich IA Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study Alcohol Fayettev N 42 675 682 2008 PMC2630703 19038698
  64. [76]Stadlbauer V Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis J Hepatol 48 945 951 2008 18433921
  65. [77]Chen P Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice Gastroenterology 148 203 214.e16 2015 25239591 PMC4274236
  66. [79]Das K Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease Hepatol Baltim Md 51 1593 1602 2010 20222092
  67. [80]Caporaso JG QIIME allows analysis of high-throughput community sequencing data Nat Methods 7 335 336 2010 20383131 PMC3156573
  68. [81]Schloss PD Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities Appl Environ Microbiol 75 7537 7541 2009 19801464 PMC2786419
  69. [82]White JR Nagarajan N Pop M Statistical methods for detecting differentially abundant features in clinical metagenomic samples PLoS Comput Biol 5 e1000352 2009 19360128 PMC2661018
  70. [83]Cole JR Ribosomal Database Project: data and tools for high throughput rRNA analysis Nucleic Acids Res 42 D633 642 2014 24288368 PMC3965039
  71. [84]Segata N Metagenomic biomarker discovery and explanation Genome Biol 12 R60 2011 21702898 PMC3218848
  72. [87]Abubucker S Metabolic reconstruction for metagenomic data and its application to the human microbiome PLoS Comput Biol 8 e1002358 2012 22719234 PMC3374609
  73. [89]Treangen TJ MetAMOS: a metagenomic assembly and analysis pipeline for AMOS Genome Biol 12 1 25 2011 PMC4053804 23320958
  74. [90]Michail S Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease FEMS Microbiol Ecol 91 1 9 2015 25764541 PMC4358749
  75. [91]Raman M Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 11 868 875 e1 3 2013 23454028
  76. [92]Matsushita N Effect of Lipopolysaccharide on the Progression of Non-Alcoholic Fatty Liver Disease in High Caloric Diet-Fed Mice Scand J Immunol 2015 10.1111/sji.12397 26524607 · DOI
  77. [94]Okubo H Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model Am J Physiol Gastrointest Liver Physiol 308 G151 158 2015 25428903

Authors
Betrapally, N. S., Gillevet, P. M., & Bajaj, J. S.
Affiliations
  • George Mason University (US)
  • Virginia Commonwealth University (US)
Corresponding author
Bajaj, Jasmohan S.
ORCID
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2016-06
Volume
150
Issue
8
Pages
1745-1755.e3
ISSN
0016-5085 (ISSN-L)
DOI
10.1053/j.gastro.2016.02.073
PMC
PMC5026236
OpenAlex
W2292532067
Cited by
123
References
99
Citations by year
2026: 1 · 2025: 10 · 2024: 10 · 2023: 9 · 2022: 7 · 2021: 14 · 2020: 20 · 2019: 16 · 2018: 16 · 2017: 15 · 2016: 4
FWCI
1.54
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Veterans Affairs (I01 CX001076)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087913)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
gut microbiota, alcoholic liver disease, non-alcoholic fatty liver disease, liver cirrhosis, alcohol cessation, intestinal integrity, diabetes mellitus, microbial treatment, pathogenesis
MeSH terms
Gastrointestinal Microbiome, Fatty Liver, Alcoholic, Humans, Intestines, Liver, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review